RGN today had a new petent filing published at the U.S. Patent office. It basically is for TB 4 in the heart area for "wound" repair. RGN has had better success in getting "wound repair" at USPO than they have with terms like skin, cosmetic or cell repair. The filing is very detailed, and uses quite a bit of examples done in animals on a range of things. Like cornea stuff. LAter in heh filing they go into a lot of detail regarding diseases where an over abundance of TB 4 may be an issue. And for that RGN shows an "antagonist TB 4". The specific application noted is cancers. If TB 4 aids growth of new blood vessels, and a tumor needs blood vessels to grow (and then kill), removing that vessel growth can "starve" a cancerous tumor. This is angiogenisis and "anti-angiogensis".
I think RGN spent a LOT of time on the wording of this patent. It just seems better. RGN has years of responses by the USPO (negative). I think maybe they have it worded right this time? Again, NOTE the focus wording on "wound repair".and RGN has success at USPO for that area! here is, pls read it: OH! note the NIH involvement! Filing is more in GOV'T name, which may help!
While we can hope...also have to be realistic. The USPO is all but impossible to deal with. And for some reason, they, RGN and RGN's lawyers...just don't "communicate" easily. Sort of like the Wardens line in the movie Cool Hand Luke.
I'd like to know what effect the new drug laws have. As it went, a new approved drug is now given 13 years exclusivity. So could RGN still get 13 years exclusivity on an indication..if ever approved...and have those 13 years even though they don't have a patent? A petent is far preferable.....but if they can get 13 years exclusive, that isn't shabby.
<<Thus, in another embodiment, the invention provides a method of inhibiting angiogenesis in a subject, including administering to the subject a composition containing an agent which regulates T.beta.4 activity. The composition may include agents that regulate angiogenesis, for example agents that affect thymosin .alpha.1, PDGF, VEGF, IGF, FGF and TGF.beta.. For example, the inhibition of angiogenesis and endothelial cell migration can be beneficial in controlling the growth of solid tumors. Most, if not all solid tumors, like normal tissue, require a steady and sufficient blood supply for optimal growth. Tumors are known to make use of angiogenic growth factors to attract new blood vessels and ascertain supply with sufficient amounts of nutrients to sustain their growth. Many tumors are well vascularized and the inhibition of the formation of an adequate blood supply to the tumor by inhibition of tumor vascularization, as a result of inhibition of angiogenesis, is beneficial in tumor growth control. Without a strong blood supply, rapid and prolonged growth of tumor tissue cannot be sustained. Thus, agents that inhibit T.beta.4 activity may be used to prevent neoplastic growth. The T.beta.4 inhibiting agent may be administered orally, parenterally, topically, intravenously, or systemically. In addition, for inhibiting tumor cell proliferation and tumor growth, the agent may be administered locally directly to the tumor or as a part of a deposited slow release formulation. >>